在MINOCA患者中抗血小板治疗策略:临床实践决策的预测因素和预后影响
Emmanouil Mantzouranis1, Ioannis Leontsinis1, Panayotis K Vlachakis1
1First Department of Cardiology, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens, Vas. Sofias 114, 11527 Athens, Greece.
Journal of clinical medicine
|June 13, 2025
概括
针对冠状动脉疾病已经建立了最佳的抗血小板策略,但对于非阻塞性冠状动脉 (MINOCA) 的心肌梗塞的数据很少. 在MINOCA患者的治疗决策仍然具有挑战性,目前的策略不会影响2年的预后.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 临床实践 临床实践
背景情况:
- 在冠状动脉疾病 (CAD) 中,最佳的抗血小板策略是明确的.
- 关于非阻塞性冠状动脉 (MINOCA) 肌肉梗塞的抗血栓策略的数据有限.
- 本研究涉及MINOCA患者目前的临床实践.
研究的目的:
- 在当前的临床实践中评估MINOCA患者的抗血栓策略.
- 确定影响MINOCA治疗决策的因素.
- 评估初始治疗对2年预后的影响.
主要方法:
- 在排除其他诊断后,分析了151名MINOCA患者.
- 心脏磁共振 (CMR) 在28%的患者中证实了急性心肌梗塞 (AMI),在36%的患者中证实了Takotsubo综合征 (TTS).
- 出院时的抗血栓药物处方被记录并与临床和血管学数据一起分析.
主要成果:
- 双重抗血小板治疗 (DAPT) 或双重抗血小板治疗 (DAT) 被处方给38%的患者.
- 动脉硬化血管学证据独立预测了DAPT/DAT的使用 (OR:0.334).
- 最初的抗血栓治疗决定没有显著影响2年的预后.
结论:
- 在临床实践中,为MINOCA患者做出抗血栓策略决策是具有挑战性的.
- 诸如LVEF,动脉样硬化和先前使用抗凝剂等因素会影响治疗选择.
- 需要进一步的研究,以确定MINOCA中抗血栓策略的确切预后影响.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
01:26Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
01:22Formation of the Platelet Plug
5.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.4K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
467
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
467
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K